跳转至内容
Merck
CN
  • Integrated analysis using methylation and gene expression microarrays reveals PDE4C as a prognostic biomarker in human glioma.

Integrated analysis using methylation and gene expression microarrays reveals PDE4C as a prognostic biomarker in human glioma.

Oncology reports (2014-05-21)
Zhaoshi Bao, Ying Feng, Hongjun Wang, Chuanbao Zhang, Lihua Sun, Zhuohong Yan, Qingyang Liu, Tianzhu Guo, Mingyang Li, Xue Yang, Chuanlu Jiang, Quangeng Zhang, Tao Jiang
摘要

Hypermethylation of tumor suppressor promoters is generally accepted to indicate poor prognosis in glioma; however, the DNA methylation patterns associated with different glioma prognoses remain to be elucidated. In the present study, promoter methylation and gene expression microarrays were used to screen candidate genes between different grades of glioma. Survival analysis was performed using the Kaplan‑Meier (KM) method. Promoter methylation and protein expression of phosphodiesterase 4C (PDE4C) was examined in different grade gliomas and the correlation between PDE4C and wild-type (WT) p53 was evaluated in glioma cell lines. In addition, gene ontology and gene set variation analysis were used to examine PDE4C function. We found PDE4C exhibited promoter hypermethylation in high-grade glioma samples and hypomethylation in low-grade glioma, with PDE4C expression levels showing the reverse. This indicated PDE4C may be a candidate glioma biomarker. Through studies of PDE4C methylation and expression status in an independent cohort of 124 patient samples (56 low-grade and 63 high-grade glioma and 5 normal brain), we identified PDE4C as having significant promoter methylation and lower expression in high-grade glioma. Hypermethylation and reduced PDE4C protein expression were associated with grade progression and overall survival. In glioma cell lines, PDE4C was upregulated by demethylation treatment with 5-Aza-2'-deoxycytidine and WT p53 expression was downregulated after PDE4C siRNA suppression. Finally, we found PDE4C promoted apoptosis and inhibited migration in a U87 cell line. On the basis of these observations and the results from subset analysis, it is reasonable to conclude that PDE4C may function as a tumor suppressor by promoting apoptosis through the WT p53 pathway and inhibiting cell migration. The data show that PDE4C is downregulated through promoter hypermethylation in glioma.

材料
产品编号
品牌
产品描述

Sigma-Aldrich
L-谷氨酰胺, meets USP testing specifications, suitable for cell culture, 99.0-101.0%, from non-animal source
Sigma-Aldrich
L-谷氨酰胺, ReagentPlus®, ≥99% (HPLC)
Sigma-Aldrich
荧光素 5(6)-异硫氰酸酯, BioReagent, suitable for fluorescence, mixture of 2 components, ≥90% (HPLC)
SAFC
L-谷氨酰胺
Sigma-Aldrich
荧光素异硫氰酸酯异构体I, suitable for protein labeling, ≥90% (HPLC), powder
Sigma-Aldrich
5-氮杂-2′-脱氧胞苷, ≥97%
Sigma-Aldrich
L-谷氨酰胺, BioUltra, ≥99.5% (NT)
Sigma-Aldrich
荧光素 5(6)-异硫氰酸酯, ≥90% (HPLC)
Sigma-Aldrich
荧光素异硫氰酸酯异构体I, ≥97.5% (HPLC)
Sigma-Aldrich
L-谷氨酰胺, γ-irradiated, BioXtra, suitable for cell culture
Sigma-Aldrich
L-谷氨酰胺
Supelco
L-谷氨酰胺, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
L-谷氨酰胺, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
Sigma-Aldrich
L-谷氨酰胺, Vetec, reagent grade, ≥99%